Research library

Key finding

In STEP 1, weekly semaglutide plus lifestyle intervention reduced mean body weight by 14.9% at 68 weeks versus 2.4% with placebo.

Key finding

In STEP 5, semaglutide sustained a 15.2% mean weight reduction at 104 weeks versus 2.6% with placebo.

Key finding

In STEP 8, semaglutide reduced mean body weight by 15.8% at 68 weeks versus 6.4% with daily liraglutide.

Key finding

In SELECT, semaglutide maintained a 10.2% mean weight reduction at four years versus 1.5% with placebo across sexes, body sizes and regions.

Key finding

In adults with cardiovascular disease and overweight or obesity without diabetes, semaglutide reduced major cardiovascular events by 20% versus placebo.

Key finding

The study reports that across STEP 1, 3, 4 and 8, semaglutide 2.4 mg was associated with mean weight losses of 14.9%-17.4% in individuals with overweight or obesity without type 2 diabetes from baseline to week 68; 69%-79% of participants achieved ≥10% weight loss with semaglutide 2.4 mg.

Key finding

The study reports that initially intended to control blood glucose levels in patients with type 2 diabetes, semaglutide, a potent glucagon-like peptide 1 analogue, has been established as an effective weight loss treatment by controlling appetite.

Key finding

The study reports that more recently developed agents, in particular semaglutide, are characterized by greater efficacy with respect to lowering plasma glucose as well as body weight.

Key finding

Between June 19 and Nov 28, 2019, of 1515 adults assessed for eligibility, 961 participants (mean age 58·0 years [SD 10·0]; 398 [41%] women) were included.

Key finding

Early worsening of DR is a known phenomenon associated with the rapidity and magnitude of improvement in glycaemic control with insulin; the DRC findings in SUSTAIN 6 are consistent with this.

Key finding

Semaglutide improved fasting and postprandial glucose and lipid metabolism.

Key finding

The study reports that differences were predominantly driven by a reduced incidence of kidney failure with semaglutide versus placebo.

Key finding

The study reports that estimated mean percentage change in bodyweight from baseline to week 44 was -12·1% (SE 0·5) with semaglutide 2·4 mg versus -3·6% (0·7) with placebo (estimated treatment difference -8·5 percentage points [95% CI -10·2 to -6·8]; p<0·0001).

Key finding

The study reports that serious adverse events occurred in 12 (9%) participants receiving semaglutide 2·4 mg versus six (9%) receiving placebo.

Key finding

The study reports that semaglutide also reduced the risk of worsening heart failure events (54 [2·8%] vs 86 [4·7%]; HR 0·59 [0·41-0·82]; p=0·0019).

Key finding

The study reports that at baseline, mean (SD) HbA1c was 9·0% (0·8; 74·4 mmol/L [SD 8·3]) and mean bodyweight was 96·4 kg (21·6).

Key finding

The study reports that in exploratory efficacy analyses, treatment resulted in additional improvements in liver steatosis and biochemistry vs. semaglutide alone.

Key finding

The study reports that in this basal insulin-treated population, OW semaglutide improved glycaemic control to a greater extent than TID IAsp and provided numerically greater weight loss.

Key finding

The study reports that semaglutide is an effective once-weekly treatment option for the Chinese population.

Key finding

The study reports that reductions in HbA1c from baseline in Japanese patients were 1.0% to 1.2% (11.3 mmol/mol to 13.3 mmol/mol) and 1.4% to 1.7% (15.7 mmol/mol to 18.3 mmol/mol) for oral semaglutide 7 mg and 14 mg, respectively.